Cognitive change after methamphetamine dependence need not occur uniformly across every task. A 2020 pilot followed attention and delayed-reward choices over three months. The two outcomes moved differently, and neither can stand in for a general measure of recovery.
A treatment cohort with repeat testing
Bernhardt and colleagues enrolled 30 patients with methamphetamine dependence and 24 comparison adults matched on age, sex and education. Patients entered a methamphetamine-specific relapse-prevention program involving 15 group sessions. Initial eligibility required at least two days without illicit drug use and negative urine screening for the specified substances.
At three months, follow-up data were available for 19 of the 30 patients and 17 of the 24 comparison adults. This was therefore a small longitudinal pilot with substantial missing follow-up, rather than a complete 54-person repeated-measure experiment.
The patients’ course was not equivalent to three months of uniform, verified abstinence. The authors classified treatment as successful in 14 of 30 patients; the remaining 16 had more than one methamphetamine relapse during the study or terminated the program prematurely. Those treatment classifications should not be confused with the separate denominator of 19 patients retested.
What improved on the attention task?
At baseline, patients missed more target responses on a sustained-attention task: mean omissions were 10.63, compared with 4.00 in controls. The baseline comparison was significant (p = 0.001). Errors and average response time did not differ significantly between groups.
At follow-up, mean omissions were 5.44 in the patient sample and 4.11 in controls. The mixed-effects model found a significant group-by-time interaction for omissions (p = 0.032), consistent with a greater reduction among patients. The follow-up omission comparison was not significant.
These are task-level findings. Fewer missed targets cannot by itself establish restored everyday attention, safe driving or the absence of other cognitive difficulties.
What did not improve in parallel?
The delayed-reward task repeatedly offered a smaller immediate payment or a larger delayed payment, with one selected choice paid. Monetary amounts ranged from €0.30 to €10, and delays ranged from three to 365 days. The model estimated how steeply each person discounted delayed money.
Patients showed steeper discounting than controls. Unlike attention omissions, discounting did not show a significant change over time or a significant group-by-time interaction. Choice consistency and deliberation time also did not differ significantly between groups.
The implication is specific: an improvement in detecting targets did not demonstrate a matching change in the valuation of delayed money. Calling both outcomes “impulsivity” or averaging them into a broad recovery narrative would obscure that distinction.
Did the program cause the attention change?
The study did not include an untreated methamphetamine-dependent comparison group. Ordinary comparison adults help assess retesting effects, but they cannot isolate a specific treatment effect among patients. Abstinence, relapse patterns, treatment participation, changing circumstances and selective retention may all contribute.
Psychiatric comorbidity and medication were additional limitations. The sample was too small to examine individual diagnoses or medications reliably. Participants who completed follow-up may also differ in unmeasured ways from those who did not.
This pilot supports studying different cognitive domains separately. It does not establish the efficacy of a particular intervention, guarantee improvement after three months or show that a persistent discounting difference represents permanent damage.
Primary scientific source
Bernhardt N, Petzold J, Groß C, et al. Neurocognitive Dysfunctions and Their Therapeutic Modulation in Patients With Methamphetamine Dependence: A Pilot Study. Frontiers in Psychiatry. 2020;11:581. doi:10.3389/fpsyt.2020.00581. Original commentary on the supplied observational pilot, not a current treatment recommendation.
Leave a Reply